» Articles » PMID: 29798971

Prognostic Significance of Serum Interleukins and Soluble ST2 in Traditional Chinese Medicine (TCM) Syndrome-Differentiated Rheumatoid Arthritis

Overview
Journal Med Sci Monit
Date 2018 May 26
PMID 29798971
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND The aim of this study was to explore the possible correlations of serum interleukins and soluble ST2 (sST2) protein with clinical features and inflammatory cytokines in rheumatoid arthritis (RA) patients, as well as to assess ability of TCM (Traditional Chinese Medicine) syndromes to differentiate RA patients and evaluate prognosis. MATERIAL AND METHODS Thirty RA patients and 25 healthy individuals were enrolled. Syndrome activity was evaluated, and lab tests were performed. Serum levels of IL-10, IL-17, IL-33, and sST2 were assessed by ELISA. RESULTS Serum levels of sST2, IL-33, and pro-inflammation cytokine IL-17 were all up-regulated, while the immunosuppressive cytokine IL-10 was decreased in RA patients. Serum IL-33 level was positively associated with ESR, CRP, and RF, as well as with HAQ score, VAS score, and DAS28 scores (P<0.05). Serum sST2 level was correlated with the morning stiffness time and ESR, as well as scores of HAQ and DAS28 (P<0.05). In addition, IL-33 level was positively corelated with IL-17 (r=0.83, P<0.01) and the relative ratio of IL-10/IL-17 (r=0.904, P<0.01), and was negatively related with IL-10 (r=-0.632, P<0.01). TCM syndrome differentiation was conducted for RA patients, including the hot syndromes and cold syndromes groups. Hot syndromes RA patients had significantly more severe inflammation compared with cold syndromes patients. CONCLUSIONS IL-33 is a possible index for monitoring disease activity and inflammation condition in RA. IL-33 contributes to RA pathogenesis through unbalancing IL-10 and IL-17. In terms of TCM, hot syndromes RA presented more serious inflammation and more active disease activity, indicating a poorer prognosis.

Citing Articles

A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2.

Chatterton C, Romero R, Jung E, Gallo D, Suksai M, Diaz-Primera R J Matern Fetal Neonatal Med. 2023; 36(1):2183470.

PMID: 36997168 PMC: 10352993. DOI: 10.1080/14767058.2023.2183470.


Suppression of Tumorigenicity 2 Pro-Inflammatory Biomarker Linking Diabetes Mellitus and Periodontitis: A Pilot Study.

Navya P, Kaarthikeyan G, Raj J S, Alamoudi A, Bahammam M, Zidane B Med Sci Monit. 2022; 28:e938218.

PMID: 36377211 PMC: 9675270. DOI: 10.12659/MSM.938218.


Efficacy and Safety of Qiwei Tongbi Oral Liquid in Patients with Stable Long-Standing Rheumatoid Arthritis.

Lu W, Fang L, Zhang J Biomed Res Int. 2021; 2021:3930800.

PMID: 34725638 PMC: 8557082. DOI: 10.1155/2021/3930800.


IL-33 in Rheumatic Diseases.

Dong Y, Zhong J, Dong L Front Med (Lausanne). 2021; 8:739489.

PMID: 34589505 PMC: 8473687. DOI: 10.3389/fmed.2021.739489.


Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment.

Wang W, Wu J, Ji M, Wu C J Transl Med. 2020; 18(1):477.

PMID: 33308251 PMC: 7733302. DOI: 10.1186/s12967-020-02661-w.


References
1.
Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9):1580-8. DOI: 10.1136/ard.2010.138461. View

2.
Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer C, Viatte S . Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009; 60(3):738-49. DOI: 10.1002/art.24305. View

3.
Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G . Autoantibodies to citrullinated proteins: ACPA. Autoimmunity. 2005; 38(1):17-24. DOI: 10.1080/08916930400022582. View

4.
Lina C, Conghua W, Nan L, Ping Z . Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol. 2011; 31(4):596-605. DOI: 10.1007/s10875-011-9542-6. View

5.
Smolen J, Aletaha D . The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol. 2010; 28(3 Suppl 59):S18-27. View